secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001104659-23-086470
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents Q2 revenue $9.4M (+11% YoY); STAR-T trial enrollment complete
--------------------------------------------------------------------------

- Product sales rose 10% to $8.1M; product gross margins improved 700 bps to 74%.
- STAR-T pivotal trial for DrugSorb-ATR completed enrollment ahead of schedule; DSMB recommended completion.
- Quarterly cash burn reduced to ~$4.5M in H1 2023 from ~$11M in H1 2022.
- Appointed Alexander D'Amico as CFO effective August 7, 2023; Michael Bator named Chairman.
- Cash and restricted cash totaled $14.8M as of June 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465923086470/0001104659-23-086470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465923086470/tm2322460d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-086470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer